Regeneron Pharmaceuticals (REGN) has become the focal point of numerous activities and actions in the market lately. Various organizations have made notable alterations in their stake in the company, including
Asset Management One Co. Ltd., Banque Pictet & Cie SA, Catawba River Capital, Van ECK Associates Corp, and Empowered Funds LLC increasing their positions, while
Stratos Wealth Partners LTD and Allspring Global Investments Holdings LLC lessened their holdings. Notably, the company observes involvement in a
securities fraud lawsuit whilst an opportunity has been presented for investors to lead the action. A spotlight is on the
upcoming healthcare conference where Regeneron will showcase in March. The company also reportedly achieved
strong revenue growth in Q4 2024, meriting positive estimations from Leerink Partners for future earnings. Moreover,
Regeneron's eye drug emerged victorious in clinical trials, offering a reduced dosing schedule without compromising treatment results.
Regeneron Pharmaceuticals REGN News Analytics from Fri, 31 Jan 2025 08:00:00 GMT to Sat, 15 Feb 2025 23:01:00 GMT -
Rating -3
- Innovation 4
- Information 8
- Rumor 5
